Search
for
Sort by
Research 121–150 of 302
- A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling
- Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
- Treatment Patterns and Unmet Needs in the Management of Alopecia Areata: Results of a Physician’s Survey in the Middle East
- Efficacy and predictive markers of response to tofacitinib and baricitinib therapy in alopecia areata: A 52-week comparative cohort study
- 52993 Regulatory γδ T cells protect human scalp hair follicles from alopecia areata in vivo
- Therapeutic update on alopecia areata: a critical review of standard and emerging targeted therapies
- Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- A Review of the Evidence for and against a Role for Mast Cells in Cutaneous Scarring and Fibrosis
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report
- Scalp Microinfusion: A Novel Drug Delivery Technique for Hair Loss Treatment
- Using the Mechanisms of Action Involved in the Pathogenesis of Androgenetic Alopecia to Treat Hair Loss
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement
- Phytochemicals and novel delivery systems in alopecia management: An integrative review
- Alopecia Areata: An Updated Review for 2023
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- Lifetime incidence and healthcare disparities in alopecia areata: a UK population-based cohort study
- Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System
- Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
- Alopecia areata
- Selective blockade of γc pathway ameliorates alopecia areata in a humanized murine model
- Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Probing the Effects of Stress Mediators on the Human Hair Follicle
- Geranyl Acetate Attenuates Para-phenylenediamine-induced Cytotoxicity, DNA Damage, Apoptosis, and Inflammation in HaCaT Keratinocytes
- SRD5A3 Is Required for Converting Polyprenol to Dolichol and Is Mutated in a Congenital Glycosylation Disorder